A comprehensive, peer-reviewed breakdown of retatrutide (LY3437943) — the triple GLP-1/GIP/glucagon receptor agonist showing unprecedented weight loss results in Phase 2 clinical trials. Mechanism, clinical data, comparison with semaglutide and tirzepatide, and current research status.
Research use only. Compound Review scores vendors on documentation — laboratory certificates, lot records, pricing and company identity. Nothing on this page is guidance on human or veterinary use, dosing or health outcomes.
Peer-reviewed studies from verified investigators — linked directly to PubMed
The pivotal Phase 2 retatrutide trial was led by Ania M. Jastreboff, MD, PhD (Yale School of Medicine), published in the New England Journal of Medicine in 2023 with 1,110+ citations. This is the most cited retatrutide study to date.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff AM, Kaplan LM, Frias JP, Wu Q, Du Y, Gurbuz S, et al.
LY3437943, a Novel Triple GIP, GLP-1, and Glucagon Receptor Agonist for Glycemic Control and Weight Loss
Coskun T, Urva S, Roell WC, et al.
Is Retatrutide (LY3437943), a GLP-1, GIP, and Glucagon Receptor Agonist a Step Forward in the Treatment of Diabetes and Obesity?
Doggrell SA.
All citations link to verified PubMed records. This site does not fabricate or assign authorship — only real published investigators are listed.
Retatrutide — designated LY3437943 in clinical development and colloquially referred to as "RETA peptide" — is a synthetic acylated peptide developed by Eli Lilly and Company. It represents the most receptor-comprehensive incretin-based therapeutic currently in clinical development, functioning as a simultaneous agonist at three distinct G-protein coupled receptors: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIP-R), and the glucagon receptor (GCGR).
This triple-agonist architecture distinguishes retatrutide from all currently approved incretin therapies. Semaglutide (marketed as Ozempic and Wegovy) targets GLP-1R exclusively. Tirzepatide (Mounjaro and Zepbound) adds GIP-R agonism to the GLP-1R target. Retatrutide's addition of glucagon receptor agonism introduces a third metabolic lever — one that is theorized to drive substantially greater energy expenditure and hepatic fat mobilization than dual agonism alone.
"Retatrutide produced a mean weight reduction of 24.2% at 48 weeks in participants with obesity — a magnitude of effect approaching that of bariatric surgery and substantially exceeding any previously approved pharmacological intervention."
— Jastreboff et al., New England Journal of Medicine, 2023
The short version: Retatrutide is the next generation of the same class of drugs as Ozempic and Mounjaro — but it pulls three levers instead of one or two. Ozempic tells your brain you're full. Mounjaro does that plus improves how your body handles blood sugar. Retatrutide does both of those things and tells your body to burn more calories at rest. That's why the weight loss numbers are bigger.
Why the Phase 2 results matter: In the clinical trial published in the New England Journal of Medicine — one of the most prestigious medical journals in the world — people taking the highest dose lost an average of 24% of their body weight in under a year. To put that in perspective, that's roughly what bariatric surgery achieves. No pill or injection had ever come close to that before. It's a genuinely significant result.
Where it stands right now: Retatrutide is not approved yet — it's in Phase 3 trials, which is the final stage before FDA review. Eli Lilly (the same company that makes Mounjaro) is running those trials now. Research-grade retatrutide is available from Purgo Labs for laboratory investigation only — it is not for human use outside of clinical trial settings.
Bottom line: If semaglutide was the iPhone 12 and tirzepatide was the iPhone 14, retatrutide is the iPhone 16. Same concept, meaningfully more powerful.
Understanding retatrutide's mechanism requires appreciating how each of its three receptor targets contributes to the overall metabolic effect. The three pathways are synergistic rather than merely additive.
The pivotal Phase 2 trial for retatrutide (NCT04881760) was a randomized, double-blind, placebo-controlled study enrolling 338 adults with a BMI ≥27 kg/m² and at least one weight-related comorbidity. Participants were randomized to receive weekly subcutaneous injections of retatrutide at doses of 1, 4, 8, or 12 mg, or placebo, over 48 weeks. Results were published in the New England Journal of Medicine in 2023.
| Dose Group | Mean Weight Loss | ≥5% Loss | ≥15% Loss | ≥30% Loss |
|---|---|---|---|---|
| Placebo | 2.1% | 28% | 2% | 0% |
| 1 mg/week | 7.2% | 73% | 14% | 1% |
| 4 mg/week | 17.3% | 92% | 60% | 8% |
| 8 mg/week | 22.8% | 100% | 75% | 18% |
| 12 mg/week | 24.2% | 100% | 83% | 26% |
The 26% of participants achieving ≥30% body weight reduction in the 12 mg group is particularly notable. Prior to the GLP-1 era, such reductions were considered achievable only through bariatric surgery. The trajectory of the weight loss curve at 48 weeks had not yet plateaued, suggesting that longer treatment durations may yield even greater reductions — a hypothesis being tested in ongoing Phase 3 trials.
The incretin receptor agonist class has evolved rapidly from mono- to dual- to triple-agonism. The following comparison contextualizes retatrutide within this progression.
| Feature | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Receptor Targets | GLP-1R | GLP-1R + GIP-R | GLP-1R + GIP-R + GCGR |
| Mechanism Class | Monoagonist | Dual agonist | Triple agonist |
| Phase 2 Weight Loss | ~15% at 68 wks | ~22% at 72 wks | ~24% at 48 wks |
| Dosing Frequency | Once weekly | Once weekly | Once weekly |
| FDA Approval Status | Approved (obesity) | Approved (obesity) | Phase 3 (pending) |
| Amino Acid Count | 31 AA | 39 AA | ~40 AA |
| Half-life | ~7 days | ~5 days | ~6 days (est.) |
| Energy Expenditure Effect | Moderate | Moderate–High | High (via GCGR) |
Like semaglutide and tirzepatide, retatrutide is an acylated peptide — meaning a fatty acid chain is attached to the peptide backbone to extend its half-life by promoting reversible binding to serum albumin. This albumin-binding mechanism protects the peptide from renal clearance and enzymatic degradation, enabling once-weekly subcutaneous dosing. The precise acylation chemistry and full amino acid sequence of retatrutide remain proprietary to Eli Lilly.
Following the landmark Phase 2 results, Eli Lilly initiated the TRIUMPH Phase 3 clinical trial program for retatrutide. The program encompasses multiple trials evaluating retatrutide across obesity, type 2 diabetes, cardiovascular outcomes, and liver disease. Status as of April 2026.
Regulatory Timeline: If TRIUMPH-1 and TRIUMPH-2 results are positive (expected 2026–2027), Eli Lilly could file an NDA/BLA with the FDA in 2027. Potential approval: 2027–2028. This timeline is speculative and subject to trial results.
Regulatory submission for retatrutide is anticipated in 2026–2027, pending Phase 3 completion. If approved, it would represent the first triple incretin receptor agonist on the market and would likely compete directly with tirzepatide in the obesity and type 2 diabetes space.
The Phase 2 protocol used a stepwise dose escalation to minimize GI side effects while maximizing efficacy. All doses are once-weekly subcutaneous injections. The 12 mg dose produced the highest weight loss in Phase 2.
Initiation dose. Establish tolerability. Expect mild nausea in ~40% of subjects.
First escalation. GI side effects typically peak here, then subside.
Consolidation. Allow GI adaptation before next escalation.
Second escalation. Significant appetite suppression typically established.
Consolidation. Weight loss acceleration often observed.
Maximum dose (Phase 2 protocol). Highest weight loss efficacy observed at this dose.
Maintenance. Phase 2 data shows continued weight loss through 48 weeks at 12 mg.
Note: This titration schedule is derived from the Phase 2 protocol (Jastreboff et al., 2023). The Phase 3 TRIUMPH protocol may differ. For detailed research dosing information, see the Retatrutide Dosage Guide. This information is for research purposes only.
Purgo Labs supplies research-grade retatrutide with ≥99% purity, third-party COA verification, and cGMP-compliant manufacturing. For licensed researchers only.
View Retatrutide at Purgo LabsFor research purposes only. Not for human use.
Retatrutide reconstitutes in bacteriostatic water (BAC water). For a 5mg vial, add 2mL BAC water for a 2.5mg/mL solution. Stable for 4 weeks refrigerated. Use a 27–31G insulin syringe for subcutaneous administration.